Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set

Kalaris Therapeutics, Inc.

CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.
On non-CIC termination without cause/good reason: 12 months base salary plus COBRA.
On CIC termination: 18 months base salary, 150% target bonus lump sum, 18 months COBRA, full equity acceleration.
CAO Hagen gets 9 months base salary (non-CIC) or 12 months plus 100% target bonus lump sum (CIC) and equity acceleration.
Both agreements require release and continued compliance with restrictive covenants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.